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Abstract
Introduction: Osteopontin (OPN) has been implicated as a mediator of Th17 regulation via type I interferon (IFN)
receptor signaling and in macrophage activity at sites of tissue repair. This study assessed whether increased
circulating plasma OPN (cOPN) precedes development of organ damage in pediatric systemic lupus erythematosus
(pSLE) and compared it to circulating plasma neutrophil gelatinase-associated lipocalin (cNGAL), a predictor of
increased SLE disease activity.
Methods: cOPN and cNGAL were measured in prospectively followed pSLE (n = 42) and adult SLE (aSLE; n = 23)
patients and age-matched controls. Time-adjusted cumulative disease activity and disease damage were
respectively assessed using adjusted-mean SLE disease activity index (SLEDAI) (AMS) and SLICC/ACR damage index
(SDI).
Results: Compared to controls, elevated cOPN and cNGAL were observed in pSLE and aSLE. cNGAL preceded
worsening SLEDAI by 3-6 months (P = 0.04), but was not associated with increased 6-month AMS. High baseline
cOPN, which was associated with high IFNalpha activity and expression of autoantibodies to nucleic acids,
positively correlated with 6-month AMS (r = 0.51 and 0.52, P = 0.001 and 0.01 in pSLE and aSLE, respectively) and
was associated with SDI increase at 12 months in pSLE (P = 0.001). Risk factors for change in SDI in pSLE were
cOPN (OR 7.5, 95% CI [2.9-20], P = 0.03), but not cNGAL, cumulative prednisone, disease duration,
immunosuppression use, gender or ancestry using univariate and multivariate logistic regression. The area under
the curve (AUC) when generating the receiver-operating characteristic (ROC) of baseline cOPN sensitivity and
specificity for the indication of SLE patients with an increase of SDI over a 12 month period is 0.543 (95% CI 0.347-
0.738; positive predictive value 95% and negative predictive value 38%).
Conclusion: High circulating OPN levels preceded increased cumulative disease activity and organ damage in SLE
patients, especially in pSLE, and its value as a predictor of poor outcome should be further validated in large
longitudinal cohorts.
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Introduction
The rapid and early accrual of organ damage in patients
with systemic lupus erythematosus (SLE) has been asso-
ciated with poor outcomes and increased mortality
[1-3]. Patients with pediatric-onset SLE (pSLE; age of
diagnosis < 18 years) are an important subset for the
study of disease progression. In children and adolescents
with SLE, organ damage is accumulated at increased
rates compared with adults: childhood and adolescent-
onset SLE has been associated with increased baseline
renal and neuropsychiatric involvement, with more renal
damage overall and higher mortality rates [4,5].
Despite many advances in the care of pSLE, our knowl-
edge of potential noninvasive markers or predictors of
irreversible injury is limited. Specifically studied in pSLE,
clinical factors, such as adjusted mean SLE disease activ-
ity index (AMS) and corticosteroid use, are predictive of
disease-related organ damage [6]. Additionally, neutro-
phil gelatinase-associated lipocalin (NGAL) has been
reported not only as a useful biomarker for increased glo-
bal and renal disease activity but also a predictor of
impending renal flare in pSLE [7,8]. Other promising bio-
markers for prediction of lupus nephritis flare in pSLE
cohorts include transferrin, alpha1-acid-glycoprotein, and
lipocalin-type prostaglandin-D synthetase, and in adult
SLE (aSLE) cohorts, monocyte chemotactic protein-1,
macrophage colony stimulating factor, regulated on acti-
vation, normal T expressed and secreted and hepcidin
isoforms [9-13].
Osteopontin (OPN), a pluripotent secreted and intracel-
lular phosphoprotein, has recently been implicated in the
pathogenesis of autoimmunity. Although OPN has not
been confirmed as an SLE-susceptibility gene, genetic
variants in OPN have been associated with increased IFN-
a pathway activation in young people with SLE, and with
specific clinical phenotypes [14,15]. Intracellular OPN pro-
motes expression of IFN-a in murine plasmacytoid
dendritic cells, and contributes to Th17 cell commitment,
which may be negatively regulated by IFN-a receptor
signaling [16,17]. In support of the role of OPN in SLE
pathogenesis, humans with SLE and autoimmune-prone
mice (MRL-lpr/lpr) have increased OPN peripherally and
in diseased tissue, which correlates with disease activity in
humans [18,19].
When expressed by macrophages and activated T cells,
OPN emerges as a key regulator of tissue repair in the con-
text of inflammation [20-22]. Deficits in expected macro-
phage accumulation have been noted in OPN-null mice
when challenged with chronic inflammatory conditions,
such as granulomatous disease [23,24]. Growing evidence
indicates that OPN splicing variants can provide diagnostic
and/or therapeutic targets for several cancers due to func-
tional diversity among OPN isoforms, particularly in terms
of increased migratory and metastatic potential [25-29].
Importantly, in murine lupus nephritis, a specialized subset
of macrophages known as alternatively activated macro-
phages, which participate in tissue repair, express OPN and
mediate aggressive proliferative lesions with enhanced cres-
cent formations [30]. OPN levels are associated with ather-
osclerosis and coronary artery disease, and in these
plaques, serve as a chemotactic agent for infiltrating
macrophages [31-34]. Phosphorylation of OPN is required
for integrin binding and subsequent induction of IL-12
expression in macrophages, and for mediating their activa-
tion and spreading [23,35]. The phosphorylation status of
OPN is at least in part mediated by tartrate-resistant acid
phosphatase (TRAP), an enzyme inversely correlated with
disease activity in pSLE [36]. Alternatively activated macro-
phages have similarly been associated with asthma-related
airway remodeling, dermatomyositis skin lesions, and scler-
oderma-associated lung fibrosis, implicating a role in organ
damage [37-39].
Based on the potential critical roles of OPN in IFN-a
pathway signaling and dysregulated post-inflammatory tis-
sue repair, we hypothesized that increased circulating
plasma OPN (cOPN) levels precede the development of
organ damage in pSLE and possibly aSLE. We compared
cOPN with circulating plasma NGAL (cNGAL), a marker
of pSLE disease flare, to investigate the potential for base-
line cOPN to predict cumulative disease activity and organ
damage. A biomarker of future disease course, particularly
in pSLE, which is associated with more aggressive disease,




All pSLE patients up to age 21 years who attended the
clinic at the University of California, Los Angeles (UCLA)
between September 2007 and January 2010 were offered
the opportunity to enroll in the prospective cohort study.
Children and young adults, fulfilling at least four of eleven
of the American College of Rheumatology (ACR) 1997
revised classification criteria for SLE prior to age 18 years
(defined as pSLE) were followed during routine visits at
pediatric rheumatology clinics (n = 42) [40]. At each study
visit, anti-dsDNA antibodies, complement (C)3 and C4
levels, erythrocyte sedimentation rate (ESR), serum creati-
nine, and urine analysis and microscopy were measured in
the UCLA clinical laboratory, using standard methods.
Antibodies to extractable nuclear antigens were measured
at study entry. Healthy, unrelated age-matched (± 5 years)
children and adolescents recruited from the UCLA pedia-
tric clinics and the undergraduate campus served as con-
trols (n = 22). All research procedures were conducted
with the approval of the UCLA Institutional Review
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Board. All the patients who participated in the study, in
addition to a parent or guardian in the case of individuals
who were minors at the time of enrollment, signed appro-
priate consent documents detailing their voluntary partici-
pation in the study and permission to publish de-identified
results from the research proceedings.
Samples obtained from an independent aSLE cardio-
vascular risk cohort with at least 12 months of complete
prospective follow up were analyzed (if the samples con-
tained an adequate amount of plasma), and clinical data
and scored outcome measures were also studied [41]. All
aSLE samples were from patients who consented to share
samples for other SLE research and were seen by physi-
cians in the UCLA Division of Rheumatology-Medicine
(n = 23). All adult control samples (n = 40) were enrolled
in the UCLA SLE genetics study, and were matched for
age and gender with the adult SLE samples [42].
Patient medical records were reviewed for any kidney
biopsy classification. At our center, kidney biopsies are
performed on all patients with pSLE who have abnormal
findings on urinalyses that cannot be explained by non-
SLE-related mechanisms. The UCLA renal pathologists
currently utilize the International Society of Nephrol-
ogy/Renal Pathology Society (ISN/RPS) system of renal
biopsy classification in lupus nephritis [43].
Osteopontin and NGAL assays
Baseline peripheral blood samples from each participant
were collected for intact plasma OPN and NGAL testing
using ELISA (RnD Systems, Minneapolis, MN, USA).
The inter- and intra-assay coefficients of variation were
5 to 10%. All measurements were made in duplicate and
conducted by an investigator who was blinded to the
identity of the subject. The plasma OPN includes both
secreted OPN and any intracellular OPN that has been
released by dying cells.
We define high cOPN as any value above the bottom
three quartiles of healthy controls (n = 62; quartiles uti-
lized as values are skewed to the right in the adult cohort)
and also perform the high cOPN analyses utilizing a cutoff
of two SD above the mean for young, healthy controls
(mean age 20.2 years; n = 22). Our healthy, young unre-
lated controls most likely represent close-to-true normal
values of cOPN, given the Gaussian distribution of the
levels in that group.
Reporter cell assay for interferon-alpha
A reporter cell assay for IFN-a activity was used as pre-
viously described [44,45]. Results from the IFN-a assay
were standardized to a healthy multi-ancestral reference
population as previously described, and a serum IFN-a
activity score was calculated based upon the mean and SD
of the reference population [44].
Disease activity and damage
Global SLE disease activity was measured using the Safety
of Estrogens in Lupus Erythematosus: National Assess-
ment (SELENA) version of the SLE Disease Activity Index
(SLEDAI; range 0 to 105). Renal disease activity was
assessed using the renal component of the SLEDAI score;
flare was assessed using the SELENA flare instrument.
Cumulative disease activity (adjusted-mean SLEDAI, or
AMS) was calculated by measuring the area under the
curve of serial SLEDAI measurements [46]. Organ damage
was measured by the Systemic Lupus International Colla-
borating Clinics/American College of Rheumatology SLE
Damage Index (SDI; range 0 to 47). No SDI was calculated
at study enrollment if: (a) diagnosis was less than 6 months
prior to the time of blood draw; or (b) available medical
records were inadequate to assess SDI at enrollment, due
to transfer of care, et cetera (6 months of clinical data is
required to accurately calculate SDI).
Longitudinal study design
Patients with pSLE were followed prospectively every 3
months and at the time of disease flare for at least 12
months. Blood draws for cOPN and cNGAL measure-
ment were obtained at baseline. SLEDAI and laboratory
parameters were recorded at 0, 3, 6, 9 and 12 months,
and at disease flare, and SDI was determined at 6 and
12 months. Only pSLE patients with one year of com-
plete follow up at UCLA subsequent to study enrollment
were included in the study. Patient samples and clinical
data, including SLEDAI and SDI, from the prospectively
collected UCLA aSLE cohort were used for confirmation
and expansion of the results. Cumulative lifetime steroid
exposure was calculated and scored as previously
described, utilizing 20 g as a cutoff for high cumulative
exposure in an adult or child heavier than 50 kg, or
300 mg/kg in a child below 50 kg [41].
Statistical analysis
All statistical analyses were performed using R statistical
package [47]. cOPN was the primary measure in this
study and data that were not normally distributed were
log-transformed when required, in order to fit major
assumptions of parametric statistical models in analysis.
Differences between two groups were examined initially
using Student’s t-test for continuous variables, and Fish-
er’s exact test for categorical variables. Correlations
between two groups were evaluated using the Pearson
test for parametric variables. Univariate analyses were
performed to assess the effect of variables on AMS and
SDI; in order to estimate effect size multiple logistic
regression was performed and this included variables pre-
viously associated with SDI, particularly in pSLE [5,6,48].
P-values ≤ 0.05 were considered statistically significant.
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Results
Demographics of the pSLE and aSLE cohorts
Forty-two individual pSLE patient plasma samples with
one year of subsequent complete clinical data were
included for analysis. The mean age of diagnosis of the
pSLE patients was 12.7 ± 4.1 years, with an age of enroll-
ment of 15.9 ± 3.5 years (demographic and disease charac-
teristics; Table 1). The pSLE cohort included twenty-one
patients (50%) who self-identify as Hispanic, ten (24%) as
Asian, five (12%) as Caucasian (non-Hispanic), four (9%)
as African-American, and two (5%) identify as other/
mixed background. The aSLE cohort was differently
distributed, with thirteen (56%) of the patients identifying
as Caucasian (non-Hispanic) and the remainder of the
cohort comprised of two patients (9%) who self-identify as
Hispanic, two as Asian, four (17%) as African-American,
and two who identify as other/mixed background.
Although both the pSLE and aSLE cohorts were estab-
lished at the same urban tertiary referral center, discordant
ethnic/racial representation may reflect differences in
insurance status. In California, all financially eligible pSLE
patients under age 21 years qualify for state-administered
health insurance, whereas most patients with SLE over age
21 years do not qualify for similar benefits.
A range of disease activity was represented at enroll-
ment, however the two cohorts approximated each other
with mean SLEDAI score in pSLE of 2 (range 0 to 15)
and in aSLE of 3 (range 0 to 12). Similarly, the mean SDI
of 0.9 at baseline was the same for the two cohorts (range
0 to 5 in pSLE, and 0 to 2 in aSLE), although the disease
duration at enrollment was less in pSLE (3.1 ± 3 years)
compared with aSLE (7.9 ± 8.6 years, P = 0.002). There
was a significant difference in kidney disease, with 71% of
the pSLE cohort having renal involvement diagnosed at,
or prior to, the initial study visit, compared with 22% in
aSLE (P = 0.0005).
Increased circulating plasma OPN levels are associated
with pSLE and aSLE
Patients with pSLE were evaluated at baseline for several
parameters by cross-sectional analysis. cOPN was
increased in the total pSLE sample compared with healthy,
unrelated age-matched controls (ages 17 to 22 years; mean
± SD: 20.3 ± 1.3 years): median 5.7 ng/ml in controls vs.
8.8 ng/ml in pSLE (P = 0.03) (Figure 1A). Similar results
were seen when comparing cOPN in aSLE with healthy,
unrelated age-matched controls: median 7.5 ng/ml in con-
trols vs. 13.0 ng/ml in aSLE (P = 0.02) Figure 1A). cNGAL
was also increased at baseline in both the pSLE cohort and
the aSLE cohort compared with the age-matched controls:
17.7 ng/ml in controls vs. 23.5 ng/ml in pSLE (P = 0.02);
21.0 ng/ml in controls vs. 31.7 ng/ml in aSLE (P = 0.04).
Interestingly, cOPN was slightly increased in the healthy
adult controls (ages 25 to 67 years; mean 41 ± 10.6 years)
compared with the young healthy controls, although not
significantly (median 7.5 ng/ml in adults vs. 5.7 ng/ml in
Table 1 Baseline characteristics of patients in the longitudinal pediatric- and adult-onset systemic lupus
erythematosus (pSLE and aSLE) cohorts*
pSLE Pediatric controls aSLE Adult controls
Sex, ratio, male:female, 10:32 10:12 2:21 16:24
Ethnicity/race, n (%)
Hispanic 21 (50) 5 (23) 2 (9) 6 (15)
Asian 10 (24) 10 (45) 2 (9) 13 (32)
Caucasian 5 (12) 6 (27) 13 (56) 16 (40)
African-American 4 (9) 1 (5) 4 (17) 4 (10)
Other/Mixed 2 (5) 0 2 (9) 1 (3)
Age, years 15.9 ± 3.5 20.2 ± 1.3 42 ± 15 41 ± 10
Age at diagnosis, years 12.7 ± 4.1 32 ± 15
Disease duration, years† 3.1 ± 3 7.9 ± 8.6
SLEDAI, mean (range) 2.0 (0, 15) 3.0 (0, 12)
SDI, mean (range) 0.9 (0, 5) 0.9 (0, 2)
Glomerulonephritis, n (%)†† 30 (71) 5 (22)
Class II 0 0
Class III 0 0
Class IV 17 (40) 4 (17)
Class V 6 (14) 0
Mixed 5 (12) 0
*Except where indicated otherwise, values are expressed as the mean ± SD and were obtained at the time of study entry. SLEDAI, Systemic Lupus Erythematosus
Disease Activity Index; SDI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index; Glomerulonephritis classification
as per the International Society of Nephrology/Renal Pathology Society. There was no biopsy done on one aSLE patient with clinical criteria of SLE renal disease.
†P = 0.002 in pSLE compared with aSLE; ††P = 0.0005 in pSLE compared with aSLE.
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young controls, P = 0.18). Although cOPN was higher in
the aSLE vs. the pSLE patients (median 13.0 ng/ml vs. 8.8
ng/ml, P = 0.04), there was no correlation of cOPN with
increasing age in the combined controls (r = 0.21, P-value
= 0.2), or in the combined SLE patients (r = 0.07, P-value
= 0.4). Despite differences in ethnic/racial distribution, no
difference was seen when comparing cOPN in Caucasian
(non-Hispanic) patients vs. a combined group of Hispanic
patients plus patients of African-American, Asian and
mixed race descent (cOPN: 19.9 ± 4.5 and 20.3 ± 4.2
ng/ml, respectively, P = 0.4)
High IFN-a activity was observed more frequently in
pSLE with baseline cOPN in the top vs. the bottom quar-
tile (43% vs. 27%, P = 0.02). As in previous studies, pSLE
patients with active (SLEDAI ≥ 4) compared with less
active disease were more likely to have high IFN-a activity
(high IFN-a activity was observed in 50% vs. 18% of pSLE
patients with active vs. less active disease, P < 0.0001) [49].
However, no association between increased IFN-a activity
and SDI was observed (high IFN-a activity was seen 21%
vs. 26% of pSLE with SDI scores of 0 vs. > 0, P = 0.5).
Increased cumulative disease activity is associated with
increased SDI scores
Bivariate analysis revealed that pSLE and aSLE patients
with an increase in SDI score over the course of the
study period also had increased AMS, a time-adjusted
measurement of cumulative disease activity (pSLE: AMS
2.3 vs. 6.2, P = 0.0007; aSLE: AMS 2.8 vs. 4.6, P = 0.03)
(Figure 1B), confirming previously described results [50].
Overall, there was no difference in AMS in pSLE com-
pared with aSLE (mean AMS 3.4 vs. 3.1, respectively).
Figure 1 Indicators of disease and cumulative disease activity in pediatric- and adult-onset systemic lupus erythematosus (pSLE and
aSLE). (A) Circulating plasma osteopontin (cOPN) and neutrophil gelatinase-associated lipocalin (cNGAL) levels in pSLE and aSLE are increased
compared with unrelated age-matched healthy young controls (H.C.) and unrelated healthy adults (H.A.), respectively. pSLE patients with active
disease are represented by open squares. (B) Increased 6-month adjusted-mean SLE disease activity index (AMS) is seen in pSLE and aSLE
patients who have an increase in Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) damage
index scores (SDI) at the end of the 12-month follow up period.
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Increased plasma NGAL levels are associated with
worsening SLEDAI scores
When baseline SLEDAI was evaluated independently of
AMS, there was no correlation at the time of blood draw
with cOPN (r = 0.09, P = 0.6) or with cNGAL (r = -0.18,
P = 0.3) in the pSLE sample. Conversely, there was an
association of increased cNGAL with worsening SLEDAI
in pSLE (Figure 2A); the threshold between persistently
inactive or active disease was characterized by a SLEDAI
of 4 over the 6-month period, and improved or worsening
was defined as a threshold SLEDAI change of greater than
or equal to 4 compared to baseline. Although there was
no association of cOPN with future flare (P ≥ 0.6) in either
the pSLE or aSLE longitudinal cohorts, when pSLE and
aSLE patients were grouped by highest or lowest quartile
cOPN at baseline (See Table 2 for clinical features), mean
AMS at 6 months was increased in subjects with high
baseline cOPN (pSLE: 5.3 vs. 2.1, P = 0.01; aSLE: 4.6 vs.
2.7, P = 0.01) (Figure 2B), but not in subjects with baseline
cNGAL in the top quartile (Figure 2B).
High plasma OPN levels are associated with autoantibody
profile
Patients with pSLE and aSLE were grouped by bottom and
top quartile of cOPN for comparison at baseline. Patients
who were positive for antibodies to dsDNA at study
enrollment were more likely to have high cOPN (P <
0.0001 for pSLE and aSLE) (Table 2). Similarly, the per-
centage of patients that demonstrated positivity for antibo-
dies to RNA-binding proteins (anti-SSA/SSB and/or anti-
Sm/RNP antibodies) was higher in the group of patients
with high cOPN (P = 0.003 and 0.0005 in pSLE and aSLE,
respectively) (Table 2). The mean ESR was higher in
patients with high cOPN (P = 0.01 and 0.1 in pSLE and
aSLE, respectively) (Table 2), despite no difference in SLE-
DAI or complement levels among these groups. Overall,
there was a higher amount of cumulative (lifetime) predni-
sone exposure among the pSLE patients with high cOPN
(P = 0.01) (Table 2). Furthermore, although the portion of
patients with renal involvement was higher in the high
cOPN quartile vs. low cOPN, these differences did not
reach statistical significance (8/11 and 8/16, respectively in
pSLE; 4/11 and 0/4, respectively in aSLE) (Table 2).
Increased circulating plasma OPN levels precede
increased 6-month cumulative disease activity and 12-
month SDI changes in pSLE and aSLE
Increased cOPN at baseline correlated with increased
AMS over the subsequent 6 months in pSLE (r = 0.51, P =
0.001) (Figure 2C), as well as in aSLE (r = 0.52, P = 0.01).
A subgroup analysis of pSLE patients with renal involve-
ment (n = 32) demonstrated similar results (r = 0.44, P =
0.02); cOPN in renal patients with active renal SLEDAI
scores (n = 13; scores for renal categories of the SLEDAI
assessment ≥ 4) showed a trend towards increased levels
(26 ng/ml vs. 12 ng/ml, P = 0.1), suggesting increased
cOPN is present in patients with renal flare. Correlation
between cNGAL and AMS was not observed (Figure 2D).
At the baseline visit, bivariate analysis revealed pSLE
patients with any organ damage (SDI > 0; n = 16) had
increased cOPN levels compared with pSLE patients
with no damage (median 18.5 ng/ml in SDI > 0 vs. 6.6
ng/ml in SDI = 0 at enrollment, P = 0.02). In addition,
SDI scores at enrollment correlated with increased
cOPN (r = 0.43, P = 0.005). Of 42 pSLE patients, 7
(16%) had an increase in SDI over the 12-month study
period, which was also associated with increased base-
line cOPN (P = 0.007) (Figure 3, top left panel); a simi-
lar trend was seen in aSLE patients (P = 0.075) (Figure
3, top left panel) and a combined analysis of pSLE with
aSLE demonstrated statistical significance (P = 0.001)
(Figure 3, bottom left panel). There was no difference in
baseline cNGAL in pSLE or aSLE with an increased
SDI, although a combined analysis of pSLE and aSLE
demonstrated a trend of lower cNGAL at baseline in
those individuals with an increase in SDI over the study
period (Figure 3, right panels).
Increased circulating plasma OPN may predict cumulative
disease activity and risk for increase in SDI in pSLE
Univariate logistic regression analysis (Table 3) did not
identify any potential factors in this cohort as associated
with high cumulative SLE disease activity (AMS > 4).
However, on univariate and multivariate analysis, high
cOPN was associated with an increase in SDI at 12 months
(odds ratio (OR) 7.5, 95% CI 2.9, 20, P = 0.03). Utilizing a
high cOPN cutoff of the bottom three quartiles of healthy
controls of all ages (n = 62) or 2 SD above the mean for
young, healthy controls (n = 22) yielded identical results;
the groups of normal versus high cOPN in this study are
not altered by the change in the cutoff. The area under the
curve (AUC), when generating the receiver-operating
characteristic (ROC) of baseline cOPN sensitivity and
specificity for the indication of SLE patients with an
increase of SDI over a 12-month period, is 0.543 (95% CI
0.347, 0.738, positive predictive value 95%, negative predic-
tive value 38%).
Discussion
In this study, we describe the potential for circulating
plasma OPN levels to determine the odds of accruing
organ damage in SLE after one year. We have shown that
increased cOPN precedes increased cumulative disease
activity in SLE and an increase in disease damage score,
especially in pSLE. This relationship with cumulative dis-
ease activity and increased damage score was not seen
with cNGAL, however, increased baseline cNGAL was
associated with a worsening SLEDAI at the subsequent
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Figure 2 Association of circulating plasma osteopontin (cOPN), but not circulating neutrophil gelatinase-associated lipocalin (cNGAL)
with adjusted-mean systemic lupus erythematosus disease activity index (AMS) at the 6-month interval. (A) Baseline cNGAL in pediatric-
onset systemic lupus erythematosus (pSLE) was lower in patients with persistently inactive disease over a 6-month period, but did not
differentiate among patients with active disease at baseline, which improves (Active:I); remains persistently active (Active:P); or worsens over 6
months. (B) Increased 6-month AMS in pSLE is associated with baseline high cOPN (OPNhi; osteopontin levels in the top quartile) compared
with cOPN in the bottom quartile (OPNlo), but not with baseline high cNGAL levels (NGALhi and NGALlo, also defined as top and bottom
quartile, respectively). (C) cOPN at baseline correlates with 6-month AMS in pSLE (n = 42) and in adult-onset SLE (aSLE) (n = 23). (D) There is no
correlation of baseline cNGAL levels in the total pSLE cohort or in aSLE. SLEDAI, SLE disease activity index.
Table 2 Baseline clinical features of pediatric- and adult-onset systemic lupus erythematosus (pSLE and aSLE) patients
based on osteopontin (OPN) quartiles*
pSLE aSLE
OPNlo OPNhi P-value OPNlo OPNhi P-value
Current prednisone dosage, mg/day, median (range) 10 (0, 60) 30 (0, 40) 0.6 5 (0, 5) 12.5 (0, 60) 0.1
High cumulative prednisone dose, patients, number (%) 2 (13) 8 (73) 0.01 1 (25) 3 (27) 0.3
Current immunosuppressive use, patients, number (%) 7 (44) 7 (64) 0.6 2 (25) 5 (46) 0.6
Renal involvement, patients, number (%) 8 (50) 8 (73) 0.4 0 (0) 4 (36) 0.5
Disease duration, years 2.3 ± 2.7 4.5 ± 3.5 0.2 8.5 ± 12.3 11.8 ± 7.6 0.7
SDI, median (range) 0 (0, 3) 2 (0, 5) 0.01 0 (0, 2) 0 (0, 2) 0.9
SLEDAI, median (range) 2 (0, 8) 2 (0,16) 0.3 2 (0, 8) 4 (0, 8) 0.6
ESR 18 ± 7 54 ± 28 0.01 8 ± 6 45 ± 35 0.1
C3 100 ± 32 95 ± 40 0.7 115 ± 15 89 ± 24 0.9
C4 15 ± 5 0.7 22 ± 3.3 19.2 ± 5.5 0.3
adsDNA, % patients negative/% patients positive 46/8 40/40 < 0.0001 100/0 43/29 < 0.0001
aRBP, % patients positive 25 45 0.003 20 43 0.0005
*Except where otherwise indicated, values are expressed as mean ± standard deviation. The lowest and highest quartile of OPN (OPNlo and OPNhi) were defined
as circulating plasma OPN levels < 7.8 ng/ml (n = 16 in pSLE and 11 in aSLE) or > 19.1 ng/ml (n = 4 in pSLE and 11 in aSLE), respectively. High cumulative
prednisone dose was defined as > 300 mg/kg in pSLE and > 20 g in aSLE. SDI, Systemic Lupus International Collaborating Clinics/American College of
Rheumatology (SLICC/ACR) damage index; SLEDAI, SLE, disease activity index; ESR, erythrocyte sedimentation rate; C3 and C4, complement 3 and 4; adsDNA,
anti-dsDNA antibody; borderline positive results were not included. aRBP, anti-RNA binding protein antibody.
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clinic visit, as expected based on previous reports [8].
Following an analysis of possible factors associated with
an increase in SDI over 12 months, cOPN was identified
as potentially useful in identifying pSLE patients at risk
for serious outcomes. Although a trend of lower baseline
cNGAL levels was seen in SLE patients with an increase
of SDI at one year, low cNGAL levels were not associated
with increased cumulative disease activity or SDI increase
on univariate or multivariate regression analysis. The
findings from this study suggest the use of cOPN as a
marker of poor outcome in pSLE during 12-month follow
up, and may have broader implications for its use in
assessing the odds of poor prognosis of SLE at any age.
The value of cOPN is unique as a possible biomarker for
risk of disease damage in SLE; in this role it is providing
additional information by identifying patients who would
require closer clinical follow up over time, in comparison
with established biomarkers of impending disease flare
such as NGAL.
The prediction of risk for irreversible damage could be
critical for guiding treatment decisions in patients with
SLE, and particularly in pSLE patients who have increased
rates of organ damage and resultant higher cost of care
compared with adult patients [4-6,51-53]. In clinical
practice, the testing of cOPN may have the potential to be
more practical to clinicians for predicting damage com-
pared to AMS, a labor-intensive calculation. We used
AMS as the scale for cumulative disease activity due to its
established value in the prediction of organ damage, our
primary outcome measure, in both adult and pediatric-
onset SLE [6]. We confirmed in our study that increased
AMS is associated with increases in SDI, and importantly,
uniquely report that increased cOPN is similarly asso-
ciated with increases in SDI. An assay such as peripheral
OPN, which may quickly and easily determine that a
patient with SLE is at higher risk for worse outcome,
could lead to more effective categorization of patients in
clinical practice.
The limitation of this study is the modest size of the
cohort and the duration of follow up. Longer follow up
periods in larger groups will help determine the true pre-
dictive ability of cOPN in SLE outcomes over time.
Although it was not the primary intention of this study to
determine whether cOPN fluctuates with disease activity
or flare, future study should include a score that captures
changes in disease activity over time, such as the British
Isles Lupus Assessment Group index, or include novel
pSLE flare criteria; particular attention should be given to
Figure 3 Baseline circulating osteopontin levels correlated with disease-related damage accumulated over the subsequent twelve months.
Mean baseline natural log-transformed circulating osteopontin (lncOPN) was higher in pediatric- and adult-onset systemic lupus erythematosus (pSLE
and aSLE) patients who had an increase in (SDI) scores over the 12-month study period (left), but not mean natural log-transformed circulating
neutrophil gelatinase-associated lipocalin (lncNGAL) (right). SDI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology
(SLICC/ACR) damage index.
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the renal domain as a strong correlation was seen between
increased AMS and cOPN in a subgroup of our SLE
patients with renal involvement [54]. We did not see dif-
ferences in mean cOPN between Caucasian and non-Cau-
casian SLE patients. Larger longitudinal studies would
permit the stratification of patients by race/ethnicity, as
well as by potentially important modifiers such as specific
organ involvement, presence or absence of organ damage,
and disease duration at baseline.
Interestingly, a previous comparison by Marhaug et al.
showed higher cOPN in healthy children compared with
adults [55]. In our healthy adult sample, there appeared
to be a right skew in the distribution of cOPN. There
was no overall correlation in our adult sample between
cOPN and increasing age however, suggesting that age
alone is not a factor for increased cOPN. In fact, using a
cutoff for high cOPN based on 2 SD above the mean for
young, healthy controls (whose cOPN levels were dis-
tributed normally) did not change the results, even
when including the adult controls in the analysis. It is
possible that potential confounders for increased cOPN
exist in the age range of our healthy adults for whom
full medical records were not available, such as subclini-
cal coronary artery disease [56]. Although patients with
SLE are prone to premature atherosclerosis, it is likely
that younger patients with SLE may have less athero-
sclerosis due to their young age and usually relatively
shorter disease duration; furthermore, cOPN may be an
indicator of global disease burden and not driven solely
by cardiovascular inflammation. As we expand the cohort
and continue to study the ability of cOPN in determining
risk for SLE disease progression, we may be able to iden-
tify those confounders that increase cOPN, including car-
diovascular disease, medication use, and baseline
individual characteristics, such as ancestry or gender, and
thus improve the positive predictive value of the cOPN
test, which was calculated at 95% [57]. The observed 95%
positive predictive value of a high cOPN test for damage
due to SLE in the subsequent 12 months warrant a follow
up study using a larger, independent longitudinal SLE
cohort.
In our study, we have confirmed increased cOPN in
pSLE compared with healthy, unrelated controls, and an
enrichment of anti-dsDNA and anti-RBP antibodies in
SLE patients with high cOPN. A genetic basis for familial
correlation of cOPN has not been confirmed in large-
scale genome-wide association studies of SLE genetic
susceptibility. However, OPN polymorphisms predispose
to increased OPN expression in Europeans and high
serum IFN-a activity in younger SLE patients, even
though to our knowledge, OPN has not been reported as
a IFN-a-regulated gene per se [14,58]. OPN may play a
role in SLE progression once disease is established, even
if it may not be a risk factor for initial development of
autoimmunity. The interaction of intracellular OPN with
the TLR7/9 pathway leading to the production of IFN-a
in murine plasmacytoid dendritic cells and the presence
of anti-dsDNA antibodies in OPN-expressing transgenic
Table 3 Univariate and multivariate logistic regression analysis of potential risk factors during 12-month follow up in
pediatric-onset systemic lupus erythematosus (pSLE)*
Univariate analysis Multivariate analysis
Variable AMS < 3.7 AMS > 3.7 OR (95% CI) P-value OR (95% CI) P-value
Osteopontin high 8 3 2.1 (0.39, 10.8) 0.4
NGAL high 7 2 0.8 (0.14, 4.8) 0.9
Cumulative prednisone exposure 12 3 0.7 (0.15, 3.2) 0.7
Disease duration > 2 years 16 4 0.6 (0.15, 3.2) 0.7
Renal involvement 22 7 1.4 (0.3, 8.3) 0.9
Non-Caucasian background 25 10 5.4 (0.28, 104) 0.3
Male gender 8 2 0.8 (0.04, 3.1) 0.9
ΔSDI = 0 ΔSDI > 0
Osteopontin high 6 4 9 (1.5, 60) 0.015 7.5 (2.9, 20) 0.03
NGAL low 8 2 1.3 (0.21, 8) 0.9 1.16 (0.14, 9.3) 0.9
Cumulative prednisone exposure 11 4 2.8 (0.5, 14.7) 0.4
Disease duration > 2 years 17 2 0.4 (0.08, 2.4) 0.4
Renal involvement 24 5 2.1 (0.2, 20.2) 0.9
Non-Caucasian background 28 7 3.4 (0.2, 68) 0.6
Male gender 10 0 0.6 (0.008, 3) 0.16
*Except where indicated otherwise, values reflect the number (%) of patients. Odd ratios (ORs) were determined for each variable based on a yes/no
determination in patients with pSLE (n = 42). Potential risk factors identified by univariate analysis (P ≤ 0.1) were included in the multivariate models. Total
number of SLE patients with adjusted mean SLE disease activity index (AMS) in the top quartile (AMS > 3.7) is 10; total number of SLE patients with change in
SDI (ΔSDI) greater than 0 is 7. SDI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) damage index; NGAL,
neutrophil gelatinase-associated lipocalin.
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mice suggests the importance of this molecule to autoim-
munity [16,59]. Suppression of murine Th17 by IFN-a
receptor signaling was shown to be mediated by inhibi-
tion of OPN expression [17]. OPN can be induced by
several inflammatory cytokines, including IL-1b, IFN-g
and TNF-a [60]. Extracellular OPN enhances macro-
phage migration, survival and cytokine production, play-
ing a critical role in chronic inflammation [23,35,61,62].
Alternatively activated macrophages express OPN and
may be key regulators of crescentic lupus nephritis,
asthma, and scleroderma lung disease [30,37,39].
Although cOPN may not be a specific marker for SLE, it
may be a more upstream event compared with biomar-
kers of flare such as NGAL; therefore, it may have value
as a marker for cumulative disease progression resulting
in organ damage.
Conclusions
To our knowledge, this is the first study to show that cir-
culating plasma OPN may have potential as a predictor
of increased cumulative disease activity and risk of organ
damage in pSLE. Our data raise the possibility that the
presence of OPN heralds the onset of a process that may
ultimately lead to irreversible tissue damage. OPN func-
tionally contributes to inflammation-associated fibrosis
via macrophage recruitment in acute and chronic inflam-
mation, potentially participating in an environment of
dysregulated tissue repair in SLE-affected organs
[23,24,63-65]. Further studies are needed to validate our
results in the context of both longitudinal observational
cohorts and randomized clinical trials, and to confirm
the specific roles of OPN in the process of organ damage
in SLE.
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